

**PCR-/NAT *Helicobacter pylori***  
**(RV 533) November 2024**



**Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.**  
*Sample composition and expected results.*

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
533A 241015 01	<b>+</b>	<b>61/71</b>	<b><i>Helicobacter pylori</i> (~ 2x10<sup>4</sup> CFU/mL)</b> Clarithromycin resistant (GGA mut. in 23S rDNA)
533A 241015 02	<b>+++</b>	<b>61/71</b>	<b><i>Helicobacter pylori</i> (~ 2x10<sup>6</sup> CFU/mL)</b> Clarithromycin resistant (GGA mut. in 23S rDNA)
533A 241015 03	<b>++</b>	<b>61/71</b>	<b><i>Helicobacter pylori</i> (~ 2x10<sup>5</sup> CFU/mL)</b> Clarithromycin resistant (GGA mut. in 23S rDNA)
533A 241015 04	<b>∅</b>	<b>62</b>	<b><i>Escherichia coli</i> K12</b>

**Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.**  
*Absolute numbers of reported individual results.*

<b>n = 59</b>	<b>Proben Nr. (Sample no.)</b>				<b>Inhibition</b>				
	<b>01</b>	<b>02</b>	<b>03</b>	<b>04</b>		<b>01</b>	<b>02</b>	<b>03</b>	<b>04</b>
<b>Befund</b> <i>Result</i>									
<b>Positiv</b>	<b>58<sup>1)</sup></b>	<b>59<sup>1)</sup></b>	<b>58<sup>1)</sup></b>	<b>2</b>	n.d.	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Negativ</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>56</b>	nein <i>no</i>	<b>59</b>	<b>539</b>	<b>59</b>	<b>59</b>
<b>Fraglich</b> <i>Questionable</i>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	ja <i>yes</i>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

**Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden.**

*Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

<b>NAT-Methode</b> [Code] (total number *)	<b>NAT richtig positiv</b> <i>True positive results</i>						<b>NAT richtig negativ</b>	
	<b>01</b>		<b>02</b>		<b>03</b>		<b>04</b>	
	<b>Absolut</b> <i>Absolute</i>	<b>%</b>	<b>Absolut</b> <i>Absolute</i>	<b>%</b>	<b>Absolut</b> <i>Absolute</i>	<b>%</b>	<b>Absolut</b> <i>Absolute</i>	<b>%</b>
<b>Bruker-HAIN GenoType HelicoDR (n= 12)</b>	<b>12</b>	<b>100</b>	<b>12</b>	<b>100</b>	<b>12</b>	<b>100</b>	<b>12</b>	<b>100</b>
<b>CerTest VIASURE H pylori + Clari. (n= 3)</b>	<b>3</b>	<b>100</b>	<b>3</b>	<b>100</b>	<b>2</b>	<b>67</b>	<b>1<sup>§</sup></b>	<b>50</b>
<b>Ingenetix H. pylori ClariRes (n= 3)</b>	<b>3</b>	<b>100</b>	<b>3</b>	<b>100</b>	<b>3</b>	<b>100</b>	<b>3</b>	<b>100</b>
<b>Seegene Allplex H. pylori + ClariR (n= 13)</b>	<b>13</b>	<b>100</b>	<b>13</b>	<b>100</b>	<b>13</b>	<b>100</b>	<b>13</b>	<b>100</b>
<b>LightMix Helicobacter 23S Kit (n= 2)</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>	<b>2</b>	<b>100</b>
<b>RIDAGENE H. pylori (n= 11)</b>	<b>10</b>	<b>91</b>	<b>11</b>	<b>100</b>	<b>11</b>	<b>100</b>	<b>10</b>	<b>91</b>
<b>In house PCR assay (n= 10)</b>	<b>10</b>	<b>100</b>	<b>10</b>	<b>100</b>	<b>10</b>	<b>100</b>	<b>10</b>	<b>100</b>
<b>Other commercial tests (n= 5)</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>	<b>5</b>	<b>100</b>

The following tests are listed under "Other commercial tests": Bioeksen H.pylori/Clarithromycin Resistance qPCR Kit (1x) and Savvygen H. pylori and Antibiotic Resistance Kit (1x).

§ Fraglich *Due to reporting questionable results, the number of true results has been reduced*

**Comments:**

1. Fifty-four of the 59 participants reported results for molecular Clarithromycin-susceptibility testing. With the exception of two laboratories, all reported results were correct.